Genetic testing is transforming modern healthcare, and at the forefront of this revolution is Steve Chapman, the Chief Executive Officer of Natera. A visionary leader in cell-free DNA technology, Chapman has been instrumental in bringing groundbreaking genetic testing solutions to the market, making a profound impact on oncology, women’s health, and organ health.
Shaping the Future of Genetic Diagnostics
TWC Magazine: Since assuming the role of CEO in 2019, Chapman has overseen the launch of 20 innovative products, significantly improving patient outcomes worldwide. Under his leadership, Natera has developed some of the fastest-growing genetic tests in history, setting new standards in precision medicine.
Natera’s Groundbreaking Genetic Tests
Natera’s suite of tests is redefining personalized healthcare, with major innovations including:
- Signatera – A revolutionary molecular residual disease test for oncology, aiding in early cancer detection and recurrence monitoring.
- Prospera – A transplant assessment test that enhances organ rejection detection in kidney and heart transplant patients.
- Renasight – A genetic panel for identifying hereditary causes of chronic kidney disease.
- Panorama – A non-invasive prenatal test (NIPT) that offers highly accurate genetic screening for expecting mothers.
With a strong focus on research and development, Chapman ensures Natera remains at the cutting edge of genetic advancements.
A Legacy of Expertise in Genetic Testing
Before taking the helm as CEO, Chapman served as Natera’s Chief Operating Officer, playing a key role in scaling the company’s operations. His expertise in commercializing genetic tests was honed during his tenure at Genzyme Genetics, a leading biotechnology firm.
Chapman began his career in human genetics research at the University of California, Los Angeles (UCLA), where he helped design arrays identifying SNPs associated with multiple sclerosis. His academic background in microbiology, immunology, and molecular genetics from UCLA laid the foundation for his impactful career in the biotech sector.
Innovating the Genetic Testing Landscape
As healthcare continues to evolve, Chapman’s leadership ensures that Natera remains a trailblazer in DNA-based diagnostics. By advancing the commercialization of genetic testing solutions, he is paving the way for more accessible, accurate, and life-changing diagnostic tools.
For more insights into biotech leadership, precision medicine, and healthcare innovation, explore related articles at The Western Connect.
Copyright 2025 The Western Connect. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.